ArticleOncotarget2016
Consumption of pomegranates improves synaptic function in a transgenic mice model of Alzheimer's disease.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 67 citations in OpenAlex.
- A randomized controlled trial investigating the impact of maternal dietary supplementation with pomegranate juice on brain injury in infants with IUGR.Scientific reports · 2021Trial
- Trial
- Punica granatum L. peel extract mitigates hyperlipidemia-induced cognitive impairments in zebrafish larvae via modulating LXR signaling.Metabolic brain disease · 2026Article
- Article
- Assessment of the effect of pomegranate seed extracts on prostate cancer through cellular and animal models.Scientific reports · 2025Article
- The Impact of the Exposome on Alzheimer's Disease: The Influence of Nutrition.International journal of molecular sciences · 2025Review
- Newer Therapeutic Approaches in Treating Alzheimer's Disease: A Comprehensive Review.ACS omega · 2025Review
- Regulation of chronic neuroinflammation through dietary herbal products.Frontiers in nutrition · 2025Review
- Article
- Pomegranate (Molecules (Basel, Switzerland) · 2024Review
- Comprehensive Insights into Pathophysiology of Alzheimer's Disease: Herbal Approaches for Mitigating Neurodegeneration.Current Alzheimer research · 2024Review
- Role of BDNF Signaling in the Neuroprotective and Memory-enhancing Effects of Flavonoids in Alzheimer's Disease.CNS & neurological disorders drug targets · 2024Review
- A review of pomegranate supplementation: A promising remedial avenue for Alzheimer's disease.Heliyon · 2023Review
- Pomegranate: A Source of Multifunctional Bioactive Compounds Potentially Beneficial in Alzheimer's Disease.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Nutritional importance and industrial uses of pomegranate peel: A critical review.Food science & nutrition · 2023Review
- Functional foods and their impact on health.Journal of food science and technology · 2023Review
- Preventive and Therapeutic Effects ofInternational journal of molecular sciences · 2023Review
- Pomegranate (Foods (Basel, Switzerland) · 2022Review
- Comparison of the Impact of the Mediterranean Diet, Anti-Inflammatory Diet, Seventh-Day Adventist Diet, and Ketogenic Diet Relative to Cognition and Cognitive Decline.Current nutrition reports · 2022Review
- Improved Efficiency of Pomegranate Seed Oil Administrated Nasally.Pharmaceutics · 2022Article
Corrections and comments
- Retraction · 2025-10-16Concerns/Issues about Authorship/Affiliation · Concerns/Issues about Image · Duplication of/in Image · Investigation by Company/Institution · Investigation by Journal/Publisher · Investigation by Third Party · Original Data and/or Images not Provided and/or not Available · Upgrade/Update of Prior Notice(s) · · date of EOC unknown, html page overwrite, date estimated from notifications; see also: https://pubpeer.com/publications/2F43F5C405F2A6F38F19DD7AD7FC0D
- Expression of concern · 2023-06-26Date of Article and/or Notice Unknown · Investigation by Journal/Publisher · Notice - Limited or No Information · Updated to Retraction · · date of EOC unknown, html page overwrite, date estimated from notifications;
- Retracted
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's Disease (AD) is a progressive neurodegenerative disorder characterized by extracellular plaques containing abnormal Amyloid Beta (Aβ) aggregates, intracellular neurofibrillary tangles containing hyperphosphorylated tau protein, microglia-dominated neuroinflammation, and impairments in synaptic plasticity underlying cognitive deficits. Therapeutic strategies for the treatment of AD are currently limited. In this study, we investigated the effects of dietary supplementation of 4% pomegranate extract to a standard chow diet on neuroinflammation, and synaptic plasticity in APPsw/Tg2576 mice brain. Treatment with a custom mixed diet (pellets) containing 4% pomegranate for 15 months ameliorated the loss of synaptic structure proteins, namely PSD-95, Munc18-1, and SNAP25, synaptophysin, phosphorylation of Calcium/Calmodulin Dependent Protein Kinase IIα (p-CaMKIIα/ CaMKIIα), and phosphorylation of Cyclic AMP-Response Element Binding Protein (pCREB/CREB), inhibited neuroinflammatory activity, and enhanced autophagy, and activation of the phophoinositide-3-kinase-Akt-mammalian target of rapamycin signaling pathway. These neuroprotective effects were associated with reduced β-site cleavage of Amyloid Precursor Protein in APPsw/Tg2576 mice. Therefore, long-term supplementation with pomegranates can attenuate AD pathology by reducing inflammation, and altering APP-dependent processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.